开拓药业-B2024年中期报告

Stock Code股份代號: 9939（於開曼群島註冊成立的有限責任公司）(Incorporated in the Cayman Islands with limited liability) CONTENTS 2584142Interim Condensed Consolidated Statement ofChanges in Equity44Interim Condensed Consolidated Statement ofCash Flows45Notes to the Condensed Consolidated InterimFinancial Information47Other Information79Definitions97 Corporate InformationFinancial and Business HighlightsManagement Discussion and AnalysisInterim Condensed Consolidated Statement ofComprehensive IncomeInterim Condensed Consolidated Statement ofFinancial Position CORPORATE INFORMATION Board of Directors Executive Directors 20246 20 Dr. Youzhi TONG(Chairman of the Board and Chief Executive Officer)Dr. Xiang NIDr. Qun LU(retired on 20 June 2024) Non-executive Directors 20246 20 Mr. Weipeng GAOMs. Geqi WEIMr. Chengwei LIU(retired on 20 June 2024) Independent Non-executive Directors Dr. Michael Min XUMr. Wallace Wai Yim YEUNGProf. Liang TONG Audit Committee 20246 2020246 20 Mr. Wallace Wai Yim YEUNG(Chairman)Dr. Michael Min XUProf. Liang TONG(appointed on 20 June 2024)Mr. Chengwei LIU(retired on 20 June 2024) Nomination Committee Dr. Youzhi TONG(Chairman)Mr. Wallace Wai Yim YEUNGDr. Michael Min XU Remuneration Committee Dr. Michael Min XU(Chairman)Dr. Youzhi TONGProf. Liang TONG Joint Company Secretaries Mr. Ming Ming CHEUNGMr. Wai Chiu WONG Authorised Representatives Dr. Youzhi TONGMr. Wai Chiu WONG Registered Office Cricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands Cricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands Head Office and Principal Place ofBusiness in China 20 No. 20 Songbei RoadSuzhou Industrial ParkSuzhouJiangsuPRC Principal Place of Business in Hong Kong 202007 Suite 2007, 20th FloorTower 2, The GatewayHarbour CityKowloonHong Kong Legal Adviser 143 Ashurst Hong Kong43/F Jardine House1 Connaught PlaceCentralHong Kong Auditor 22 PricewaterhouseCoopersCertified Public Accountants and Registered Public Interest Entity Auditor22/F Prince’s BuildingCentralHong Kong Principal Share Registrar and Transfer Office Conyers Trust Company (Cayman) LimitedCricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands Hong Kong Share Registrar 183171712–1716 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th FloorHopewell Center183 Queen’s Road EastWanchaiHong Kong Principal Banks Shanghai Pudong Development BankSuzhou Branch Wuzhong Sub-branchChina Construction BankSuzhou Industrial Park Sub-branch www.kintor.com.cn Company’s Website www.kintor.com.cn 500 Board Lot Size 500 shares 9939 Stock Code 9939 FINANCIAL AND BUSINESS HIGHLIGHTS FINANCIAL HIGHLIGHTS •20236 30212.1140.666.3%20246 3071.5 •Our net loss decreased by RMB140.6 million or 66.3% fromRMB212.1 million for the six months ended 30 June 2023 toRMB71.5 million for the six months ended 30 June 2024, whichwas mainly attributable to the decrease of our Group’s researchand development costs and administrative expenses. 20236 30164.6125.376.1%20246 3039.3KX-826GT20029 •Our R&D costs decreased by RMB125.3 million or 76.1% fromRMB164.6 million for the six months ended 30 June 2023to RMB39.3 million for the six months ended 30 June 2024.Such decreased costs were mainly attributable to the Group’sincreasing focus on investments in core dermatology pipelinesKX-826 and GT20029, which have much lower costs comparedto oncology pipelines. The Company internally summarises theresults and experience of previous clinical trials, and furtherimproves the requirements and measures before conductingsubsequent clinical trials. The Group is continuing to exploredifferent approaches to further promote the commercialisationof the Company’s cosmetic products worldwide. •20236 3051.217.333.8%20246 3033.9 •Our administrative expenses decreased by RMB17.3 million or33.8% from RMB51.2 million for the six months ended 30 June2023 to RMB33.9 million for the six months ended 30 June2024. Such decrease was mainly attributable to the reductionin employee benefit and share-based compensation expensesduring the Reporting Period. •20246 30333.720246 3080.0 •The Group had cash and cash equivalents and time depositsof RMB333.7 million as at 30 June 2024. In addition, the Grouphad unutilised bank facilities of RMB80.0 million as at 30 June2024. The Group has sufficient cash on hand to support theadvancement of the Group’s clinical trials and research anddevelopment. •20246 3020236 30 •The Board resolved not to pay any interim dividend for the sixmonths ended 30 June 2024 (for the six months ended 30 June2023: Nil). BUSINESS HIGHLIGHTS 6I-III2024 As at the date of this report, we have six innovative potentialfirst-in-class/best-in-classdrug candidates at phase I-III clinicalstage. Based on the Company’s clear strategic layout in the field ofdermato